Osivax

About Osivax

Osivax is a biotechnology company focused on developing universal vaccines against constantly mutating pathogens using its proprietary oligoDOM™ nanoparticle platform technology. The company aims to provide long-term protection by triggering potent T-cell responses and combining these with antibody-based vaccines to empower both arms of the immune system. Osivax targets influenza and coronavirus infections, with plans to expand to other infectious diseases.

Products & Services

Influenza Vaccine - OVX836:A vaccine candidate targeting influenza, currently in clinical trials to demonstrate safety and efficacy.

Coronavirus Vaccine - OVX033:A vaccine candidate aimed at providing protection against current and emerging coronavirus strains.

oligoDOM™ Technology:A novel proprietary nanoparticle technology designed to trigger strong T-cell responses for universal vaccine development.

Specialties

Universal Vaccine Development T-cell Response Technology Nanoparticle Vaccine Platforms Influenza and Coronavirus Vaccines

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Award T: - FT: Award	A: 19500000 MR: - FA: $19.5M FAN: 19500000	D: 2025-08-26 FD: 2025-08-26	1 investors
2	RT: Series B T: - FT: Series B	A: 10800000 MR: - FA: €10 million FAN: 10800000	D: 2025-03-04 FD: 2025-03-04	1 investors
3	RT: Series B T: - FT: Series B	A: 10000000 MR: - FA: €10 million FAN: 10000000	D: 2025-03-04 FD: 2025-03-04	1 investors
4	RT: Series B T: - FT: Series B	A: 11000000 MR: - FA: €10 million FAN: 11000000	D: 2025-03-04 FD: 2025-03-04	1 investors
5	RT: Grant T: - FT: Grant	A: 1500000 MR: - FA: over USD 1.5M FAN: 1500000	D: 2023-12-05 FD: 2023-12-05	1 investors
6	RT: Grant T: - FT: Grant	A: 1000000 MR: - FA: over USD 1M FAN: 1000000	D: 2023-03-28 FD: 2023-03-28	1 investors

Award Latest

2025-08-26

$19.5M

1 investor (Pro only)

Series B 2025-03-04

$10.8M

Series B 2025-03-04

$10.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alexandre Le Vert

D

Dr Florence Nicolas, PhD

D

Dr Nicola Groth, MD

D

Dr. Delphine Guyon-Gellin, DVM

L

Linda Lebon

V

Vincent Bille, PhD

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

Osivax Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised